NEAT decreases, training output drops, recovery declines
In the TRIUMPH-1 Phase 3 trial, participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks, and up to 30.3% at 104 weeks in the study extension
This is a genuinely patient-first feature
Cox proportional hazards model: To estimate the hazard ratio for the time to a 5-point increase in MDS-UPDRS Part III score
Semaglutide study To determine the therapeutic potential of GLP-1RA on body composition, food intake, and glucose tolerance, we subcutaneously injected mature animals (1830 weeks old) with either vehicle (6% vol/vol DMSO in 0.9% saline) or semaglutide (0.15 mg/kg body weight
2- Cardiovascular Protection : Improves multiple risk markers, lowers heart failure, related outcomes, and reduces progression[7] to type 2 diabetes in high-risk populations